The J22352 compound promotes the degradation of aberrantly expressed HDAC6 in GBM, with the consequent autophagic-dependent cell death, block of cell migration, and tumour growth inhibition in mouse subcutaneous xenografts. Here, HDAC6 is linked to glioblastoma.